(Q38224967)

31 August 2017

title

Acquired resistance to TKIs in solid tumours: learning from lung cancer (English)

1 reference

31 August 2017

1 reference

2

William Pao

1 reference

31 August 2017

3

Lecia V Sequist

1 reference

31 August 2017

D Ross Camidge

1

1 reference

31 August 2017

language of work or name

English

0 references

publication date

1 July 2014

1 reference

Nature Reviews Clinical Oncology

31 August 2017

published in

1 reference

31 August 2017

volume

11

1 reference

31 August 2017

issue

8

1 reference

31 August 2017

page(s)

473-481

1 reference

Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

ROS1 rearrangements define a unique molecular class of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Complete response to erlotinib treatment in brain metastases from recurrent NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Treatment of leptomeningeal spread of NSCLC: a continuing challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Taking aim at ALK across the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Effects of smoking on the pharmacokinetics of erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.104

10.1038/NRCLINONC.2014.104

31 March 2020

Identifiers

DOI

1 reference

31 August 2017

1 reference